This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets. Importance Rank: 1 read more

Go to News Site